BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
September 9, 2024 12:11 PM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "Overall consistent results support advancing CK-586 into Phase 2 studies though greater conviction remains elusive for now. We reviewed the results of a Phase 1... More
Here's the list of biotech stocks that have key data catalysts in 2025
September 7, 2024 8:00 PM EDTWith only around 4 months left for 2024 to end, Piper Sandler analysts have identified 22 biotechnology stocks with key data catalysts/ approvals in 2025.
We looked at our coverage to look for data and approval driven catalysts that provide buying opportunities as the year is coming to a close, the firm told its clients in a note.
Among stocks with a market cap of over $1 billion, the firm identified 10 names.
1. Cytokinetics Inc. (NASDAQ: CYTK): With rolling submission expected to finish in 3Q24, we calculate potential aficamten oHCM... More
